Jesper Høiland made a decision, and share prices fell by 17 percent: "That's just part of taking responsibility"
The former head of Novo Nordisk in the US disappointed investors when he decided to sell two cancer drug candidates under development at his company Radius Health. It is necessary to focus the business, the CEO says.
When biotech company Radius Health released its accounting report for the third quarter in November 2019, the company exceeded analysts' expectations and adjusted its sales predictions for the year. Then one day, the company's share value dropped by 17 percent.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
